Zydus Lifesciences News and Updates

Name: Latest research reports of Zydus Lifesciences Ltd. authored by Deven Choksey and published by - Trendlyne research reports.
Item: Zydus Lifesciences Ltd.
Rating: 4
Author: Deven Choksey

Keep track of all breaking news on Zydus Lifesciences from all sources in a single place.

Zydus Lifesciences Ltd.

25 May 2026

1150.80

-0.71%

Strong Execution Across US Specialty Pipeline and Diversified Businesses Supports Long-Term Growth

Accumulate: Zydus Lifesciences Ltd.

Recommendation Target

Deven Choksey

Zydus Lifesciences is increasingly positioning itself as a differentiated specialty-led healthcare company with multiple long-term growth drivers beyond traditional generics.

Zydus Lifesciences has gained 27.55% in the last 3 Months

Zydus Lifesciences Ltd.

20 May 2026

1150.80

-0.71%

DF/EM offset moderating US business

Neutral: Zydus Lifesciences Ltd.

Target

Motilal Oswal

Zydus LifeSciences (ZYDUSLIF) delivered a better-than-expected financial performance in 4QFY26, with 9.5%/19%/11% beat on revenue/EBITDA/PAT.

Zydus Lifesciences has gained 28.60% in the last 6 Months

Zydus Lifesciences Ltd.

19 May 2026

1150.80

-0.71%

to see Rapid results content

Zydus Lifesciences Ltd.

11 Feb 2026

1150.80

-0.71%

Zydus Lifesciences (ZYDUSLIF IN) Q3FY26 Result Update US sales hinges on timely high value launches Accumulate

Accumulate: Zydus Lifesciences Ltd.

Prabhudas Lilladhar

Zydus Lifesciences (ZYDUSLIF) Q3 EBITDA was largely in line with our estimates. We believe base business remains steady with mild erosion. Though, company is working on a robust pipeline of complex products, including injectables, 505(b)2, transdermals, NCE, biosimilars and vaccines, they are expected to materialize over the next 23 years. We expect US sales to decline in FY27E given sales erosion in some of key products and thereby expect flat EPS CAGR over FY25-28E. Mgmt have guided for 2-3 high value launches over...

Number of FII/FPI investors increased from 682 to 698 in Mar 2026 qtr.

Zydus Lifesciences Ltd.

10 Feb 2026, 12:00AM

1150.80

-0.71%

Operational beat; DF/NA/international markets drive earnings

Neutral: Zydus Lifesciences Ltd.

Target

Motilal Oswal

Zydus Lifesciences (ZYDUSLIF) posted a better-than-expected operational performance in 3QFY26, with 8%/5% beat on revenue/EBITDA. Higher depreciation, interest costs and tax rate led to in-line earnings in 3Q.

Number of FII/FPI investors increased from 682 to 698 in Mar 2026 qtr.

Zydus Lifesciences Ltd.

09 Feb 2026, 02:37PM

1150.80

-0.71%

to see Rapid results content

Zydus Lifesciences Ltd.

07 Nov 2025

1150.80

-0.71%

Zydus Lifesciences (ZYDUSLIF IN) Q2FY26 Result Update US...

Accumulate: Zydus Lifesciences Ltd.

Target

Prabhudas Lilladhar

Zydus Lifesciences has gained 27.55% in the last 3 Months

Zydus Lifesciences Ltd.

07 Nov 2025

1150.80

-0.71%

Limited visibility in US beyond current exclusivities

Hold: Zydus Lifesciences Ltd.

Target

ICICI Securities Limited

Zydus Lifesciences’ (Zydus) recent acquisitions in consumer wellness and medtech divisions helped it in driving a beat in Q2FY26 revenue though subdued margins of these businesses and lower revenue of gRevlimid dragged EBITDA margin (down 28bps YoY and 426bps QoQ).

Zydus Lifesciences L.. has an average target of 1051.20 from 5 brokers.

Zydus Lifesciences Ltd.

07 Nov 2025

1150.80

-0.71%

Strong domestic and international growth offset US softness; margins moderated amid higher costs

Buy: Zydus Lifesciences Ltd.

Target

Deven Choksey

We remain constructive on Zydus Lifesciences given its improving business mix, continued progress on complex launches, and stable performance in India formulations.